Case Report: Psoriasiform Eczema with Immune-Mediated Comorbidities Treated with Upadacitinib
August 2024
in “
Frontiers in Immunology
”
New to Alopecia Areata? There is a guide in the encyclopedia. Read the guide → Studysummary In this study, upadacitinib was reported as effective in rapidly treating psoriasiform eczema in five male patients and showed varying degrees of effectiveness on other immune-mediated comorbidities like alopecia areata, vitiligo, ulcerative colitis, and hidradenitis suppurativa.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
This case report discusses the use of upadacitinib, a selective JAK-1 inhibitor, in treating psoriasiform eczema and associated immune-mediated comorbidities in 5 male patients. The treatment was effective for psoriasiform eczema, with rapid improvement in all cases. Upadacitinib also showed good effectiveness for alopecia areata, partial improvement for vitiligo, complete remission for ulcerative colitis, and slight improvement for hidradenitis suppurativa. No adverse events were reported, suggesting upadacitinib's potential as a therapeutic option for multiple immune-mediated diseases. Further studies are recommended to assess its efficacy in conditions like alopecia areata, vitiligo, and hidradenitis suppurativa.
